Key result
Cardiovascular device reimbursement cuts are being evaluated for impacts on 30-day and 1-year mortality.
Why the study?
The effect of the SUS reimbursement reduction and subsequent policy reversal for cardiovascular implantable devices and coronary stents on patient mortality in Brazil had not been evaluated.
Observational
Yes
Answers are grounded in this paper and cite their sources.
Mortality effects of cardiovascular device reimbursement cuts remain unlinked in this design; leaves open policy consequences for public-system outcomes.
Preregistered national quasi-experimental study of the effect of the reduction in SUS reimbursement for cardiovascular implantable devices and coronary stents (Ordinance GM/MS 3,693/2021, based on Technical Note 821/2021; paid from Jul-Sep/2022) and its reversal (Ordinance GM/MS 1,174/2023; from Sep/2023) on 30-day and 1-year mortality of adults hospitalized with conditions that may require a pacemaker, defibrillator, resynchronization device or stent. Public DATASUS data (SIH, SIM, CNES, SIGTAP). Hospital-level dose of exposure defined before the cut; difference-in-differences with reversal, interrupted time series and instrumental-variable analyses. Outcome data from SIM have not been examined.
No takes yet. Share an insight, caveat, or question.
Queiroga et al. (2026) conducted an observational in Conditions requiring a pacemaker, defibrillator, resynchronization device, or coronary stent. Reduction in SUS reimbursement for cardiovascular implantable devices and coronary stents (Ordinance GM/MS 3,693/2021) and its subsequent reversal (Ordinance GM/MS 1,174/2023) vs. Pre-cut reimbursement period and hospitals with lower baseline exposure was evaluated on 30-day and 1-year mortality. Reduction in SUS reimbursement for cardiovascular devices and stents is being evaluated for 30-day and 1-year mortality; outcome data have not yet been examined.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: